.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Argus Health
Deloitte
Boehringer Ingelheim
Johnson and Johnson
Chinese Patent Office
Moodys
Colorcon
Fuji
Novartis

Generated: September 19, 2017

DrugPatentWatch Database Preview

Mylan Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for MYLAN PHARMS INC, and when can generic versions of MYLAN PHARMS INC drugs launch?

MYLAN PHARMS INC has two hundred and thirty-eight approved drugs.

There are twelve US patents protecting MYLAN PHARMS INC drugs. There are twenty-nine tentative approvals on MYLAN PHARMS INC drugs.

There are two hundred and nineteen patent family members on MYLAN PHARMS INC drugs in forty countries.

Summary for Applicant: Mylan Pharms Inc

Patents:12
Tradenames:195
Ingredients:185
NDAs:238
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc
PERPHENAZINE
perphenazine
TABLET;ORAL206691-001Apr 14, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
CICLOPIROX
ciclopirox
SOLUTION;TOPICAL078567-001Sep 18, 2007DISCNNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
MESALAMINE
mesalamine
SUPPOSITORY;RECTAL204354-001Nov 24, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
CLONAZEPAM
clonazepam
TABLET;ORAL074940-002Oct 30, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
NARATRIPTAN
naratriptan hydrochloride
TABLET;ORAL202431-002May 31, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
MYCOLOG-II
nystatin; triamcinolone acetonide
CREAM;TOPICAL062606-001May 15, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
DESMOPRESSIN ACETATE
desmopressin acetate
TABLET;ORAL200653-002Jun 27, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
ESZOPICLONE
eszopiclone
TABLET;ORAL091151-001Mar 26, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
ESOMEPRAZOLE MAGNESIUM
esomeprazole magnesium
CAPSULE, DELAYED REL PELLETS;ORAL078936-001Aug 2, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
MIRTAZAPINE
mirtazapine
TABLET;ORAL076176-002Jun 19, 2003ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Mylan Pharms Inc

Paragraph IV activity for MYLAN PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
ketoconazole
Foam2%
EXTINA
7/30/2009
betamethasone valerate
Foam0.12%
LUXIQ
8/10/2007
clobetasol propionate
Topical Foam0.05%
OLUX
6/27/2005

Non-Orange Book Patents for Mylan Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,629,128Vitamin formulation► Subscribe
9,486,394Pharmaceutical foam► Subscribe
7,749,488Pharmaceutical foam► Subscribe
5,075,445 Guanine derivatives► Subscribe
5,886,215 2-acetoxymethyl-4-halo-butyl-1-yl acetates► Subscribe
5,684,153 Process for the preparation of purine derivatives► Subscribe
8,586,066Topical antifungal composition► Subscribe
5,250,688 Purine derivatives► Subscribe
6,126,920 Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition► Subscribe
8,298,515Vitamin formulation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Mylan Pharms Inc Drugs

Country Document Number Estimated Expiration
Spain2277394► Subscribe
New Zealand302727► Subscribe
Japan2001520184► Subscribe
Hungary9900801► Subscribe
Finland923371► Subscribe
Taiwan307687► Subscribe
Hong Kong218996► Subscribe
Spain2299258► Subscribe
JapanH0625241► Subscribe
China1053547► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Mylan Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014026,C1506211Lithuania► SubscribePRODUCT NAME: DAPAGLIFLOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
C0009Belgium► SubscribePRODUCT NAME: COLFOSCERIL PALMITAS (DIPALMITOYLPHOSPHATIDYLCHOLINE) (DPPC); NAT REG.: 251 IS 142 F 12; FIRST REG.: GB PL 0003/0283 19901214
C0048France► SubscribePRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
C0036Belgium► SubscribePRODUCT NAME: CHLORHYDRATE DE ROPINIROLE (=ROPINIROLE); NAT. REGISTRATION NO/DATE: 981 IS 120 F 3 19970414; FIRST REGISTRATION: GB PL 10592/0085 19960702
00214Netherlands► SubscribePRODUCT NAME: ERLOTINIB, DESGEWENST IN DE; REGISTRATION NO/DATE: 57266 01,..02,..03EU/1/05/311/001...003 20050321
2004004,C0717738Lithuania► SubscribePRODUCT NAME: LINEZOLIDUM ((S)-N-((3-(3-FLUOR-4-(4-MORFOLINIL)FENIL)-2-OKSO--5-OKSAZOLIDINIL)METIL)-ACETAMIDAS); REGISTRATION NO/DATE: 02/8199/2 20030313
00528Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN HYDROCHLOORTHIAZIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; NATL. REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION: CH 61678 01-05 20110705
C/GB09/032United Kingdom► SubscribePRODUCT NAME: PRASUGREL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/08/503/001 20090225; UK EU/1/08/503/002 20090225; UK EU/1/08/503/003 20090225; UK EU/1/08/503/004 20090225
00486Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216
2014 00038Denmark► SubscribePRODUCT NAME: TRAVOPROST; REG. NO/DATE: EU/1/01/199/001-002 20011127
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
McKinsey
US Department of Justice
Julphar
Covington
Harvard Business School
Farmers Insurance
Accenture
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot